



ADIAVET[™] A/H1N1 (2009) REAL TIME

TEST FOR THE DETECTION OF THE PANDEMIC INFLUENZA VIRUS A/H1N1/04/2009 ON PIGS BY REAL-TIME ENZYMATIC AMPLIFICATION (RT-PCR TEST)

Reference:

ADI441-50 (50 reactions) ADI441-100 (100 reactions)



NOTE

Dye compounds in this product are sold under license from Biosearch Technologies, Inc. and protected by U.S. and worldwide patents either issued or in application. The license covers Veterinary Molecular Diagnostics.

English version NE441- 09 2020/05

ADIAVET[™] A/H1N1 (2009) REAL TIME

I.	REVISION HISTORY	3
II.	GENERAL INFORMATION	4
1.	Purpose of the test	
2.	Pathogen	
3.	Description and purpose of the test	4
III.	MATERIAL AND REAGENTS	6
1.	Reagents provided with the kit	6
2.	Validity and storage	6
3.	Use of controls	
	A. A/H1N1 CTL+	
	B. SIV CTL	
4.	Equipment required but not supplied in the kit	6
IV.	RECOMMENDATION BEFORE THE ANALYSIS OF SAMPLES	8
1.	Precautions	
2.	Storage of samples and DNA extracts	
3.	Samples preparation	
	A. Nasal swab	
	B. Vral strain culture, supernatant of cellular culture, allantoidal liquids or bronchia.	
	C. Tissue	
4.	Controls to include	9
V.	EXTRACTION AND PURIFICATION	10
1.	Using RNeasy® kit	10
2.	Using QIAamp® Viral RNA kit	11
3.	Using Nucleospin® RNA kit	12
4.	Using Nucleospin® RNA Virus kit	13
5.	Using Nucleospin® 8 RNA kit	
6.	Using Nucleospin® 96 Virus	
7.	Using ADIAMAG kit	16
VI.	AMPLIFICATION	17
VII.	INTERPRETATION OF RESULTS	18
1.	Definitions	18
2.	Validation and interpretation of results	18
	A. Validation of the run	18
	B. Result interpretation	19
VIII.	INDEX OF SYMBOLS	20

I. Revision history

N/A Not Applicable (first publication)
Correction Correction of document anomalies

Technical change Addition, revision and/or removal of information related to the

product

Administrative Implementation of non-technical changes noticeable to the user

Note: minor typographical, grammar and formatting changes are not included in the revision history.

Release Date	Part Number	Change type	Change summary
2013/11	NE441-05	Correction	The supplier changed NucleoSpin® RNA II designation for NucleoSpin® RNA, in page 6, § III-4.
2013/11	NE441-05	Technical change	Addition of optional 10 μl/ml β-mercapethanol to liquid biological samples, in page 9, § V-1.
2013/11	NE441-05	Correction	The supplier changed RA2 designation for RAW2, in page 12, § IV-3.
2013/11	NE441-05	Technical change	Addition of optional 10μl/ml β-mercapethanol f to liquid biological samples, in page 11, § V-3.
2013/11	NE441-05	Technical change	Addition of definitions, in page 16, § VII-1.
2015/12	NE441-06	Technical change	Removal of reference ADI441-100 (100 reactions)
2015/12	NE441-06	Technical change	Addition of « Index of Symbols » section, in page 18, § VIII.
2016/07	NE441-07	Administrative	Changing logos
2016/07	NE441-07	Administrative	Biosearch legal mention
2016/07	NE441-07	Administrative	Addition of table "Analysis options according to the specimen" §I.3.
2016/07	NE441-07	Technical change	Addition of the optional nature of the β-mercapethanol (10μl/ml) to liquid biological samples, in page 13, § V-5.
2020/01	NE441-08	Technical change	Addition of a NF-Water tube in the kit. Addition of ADIAMAG kit using magnetic beads
2020/05	NE441-09	Technical change	Addition of reference ADI441-100 (100 reactions)

II. General information

1. Purpose of the test

ADIAVET™ A/H1N1 (2009) REAL TIME kit is intended to detect the A/H1N1/2009 Pandemic Influenza Virus (A/H1N1 Virus) using real-time Polymerase Chain Reaction (PCR) technology from nasal swab, from allantoic or bronchial fluid and tissue specimens of pig, as well as from viral culture.

2. Pathogen

The swine flu is an important pig farm disease because it could lead to severe respiratory symptoms. It is generally characterized by a high number of infected animals but a low mortality level. The disease is due to a virus of the Influenza type A genus. The first isolation of an influenza virus on pig occurs in 1930 (Influenza type A, H1N1). In opposition to the human flu, Swine flu could spread in pig farms all over the year. Three sub-types of Influenza type A virus can usually infect pigs: H1N1, H3N2 and H1N2. H1N1 and H1N2 are enzootic in Europe.

Since the April 2009, the pandemic flue due to the new variant of the influenza virus A(H1N1) rapidly spread in the worldwide human population. It is then important, for animal and human health, to identify among influenzal infections that periodically affect pig farms, those related to the pandemic influenza A/H1N1 in order to limit the disease spreading.

The detection of the virus is usually performed by viral culture on nasal swabs. Viral culture as well as diagnostic tests based on the detection of nucleoprotein antigen (such as immunofluorescence staining assay) can be carried out on lung sample. Viral culture has to be performed at an early stage of the disease because the virus persists only few days at the lesions level.

Real time PCR can be an interesting, specific and sensitive alternative method to obtain a result in one day if nasal swabs are taken on the early first clinical signs (exhaustion, fever, loss of appetite, respiratory difficulties).

3. Description and purpose of the test

This test is based first on the reverse transcription (RT) of RNA into complementary DNA. Then, cDNA is amplified (PCR) by a DNA polymerase using specific primers. Both enzymatic reactions occur in the same tube (One-step RT-PCR).

Amplified products are detected in real-time thanks to a specific labelled hydrolysis probe (5'-exonulease technology).

The ADIAVET™ A/H1N1 (2009) REAL TIME kit enables the simultaneous detection of:

- pandemic influenza virus A/H1N1/04/2009 (probe labelled in FAM),
- GAPDH, an internal control of extraction and amplification steps specific from an endogenous RNA (probe labelled with a fluorochrome read in the same spectra as VIC and HEX).

ADIAGENE validated the test using RNA purification kits (Bio-X Diagnostics, Qiagen, Macherey-Nagel). Other purification kits can be used if they have been validated by the user.

Analysis options according to the specimen:

Specimen	Individual analysis	Pool of sample is possible*, up to
Opecinien	i iliaiviaaai allaivoio	i i odi di sallible is bossible i ub to

Nasal swab		3
Allantoic or bronchial fluid	\square	X
Tissue (lung)		X
Viral culture	V	X

^{*} It depends on the epidemiological case and on the quality of the specimen. Not recommended for the diagnostic in case of clinical signs.

This test is recommended in France by the ANSES (French agency for sanitary security of foods) to detect the A/H1N1 (2009) Influenza pandemic virus in pig farms.

III. Material and reagents

1. Reagents provided with the kit

A5amplification solution	1 x 1000 µl tube with green cap (a ready-to-use reagent)
A/H1N1 CTL+positive control Pandemic Influenza Virus A/H1N1/04/2009	1 tube with purple cap (to reconstitute)
SIV CTLNegative control Swine Influenza Virus	1 tube with purple cap (to reconstitute)
NF-WaterNuclease free Water	1 x 1000 µl tube with white cap (a ready-to-use reagent)
A5amplification solution	2 x 1000 μl tubes with green cap (a ready-to-use reagent
VH1N1 CTL+positive control Pandemic Influenza Virus A/H1N1/04/2009	1 tube with purple cap (to reconstitute)
SIV CTLNegative control Swine Influenza Virus	1 tube with purple cap (to reconstitute)
NF-WaterNuclease free Water	1 x 1000 µl tube with white cap (a ready-to-use reagent)

2. Validity and storage

On receipt, the kit should be stored at <-15°C.

It is recommended to make fractions of A5 solution if it should be defrosted more than 3 times.

Do not defrost reagents more than 3 times.

Realtime reagents are susceptible to light: store them in the darkness.

The A5 reagent is ready to use for PCR reaction.

Do not mix reagents of two different batches.

3. Use of controls

A. A/H1N1 CTL+

Add 200 μ l of NF-Water to the A/H1N1 CTL+ tube included in the kit. Homogenize tube contents using a mixer such as vortex, at least 20 seconds. Use this solution like a sample RNA extract. Aliquot this solution by 6 or 12 μ l and store them to <-15°C.

For each analysis, we recommend to use $5 \mu l$ of A/H1N1 CTL+ in one of the wells. A standard range could be obtained from tenfold dilution (10-1 to 10-5) of the positive control solution.

B. SIV CTL-

Add **200 \muI** of **NF-Water** to the **SIV CTL-** tube included in the kit. Homogenize tube contents using a mixer such as vortex, at least 20 seconds. Use this solution like a sample RNA extract. Aliquot this solution by 6 or 12 μ I and store them to <-15°C.

For each analysis, we recommend to use 5 μl of SIV CTL- in one of the wells.

4. Equipment required but not supplied in the kit

Material should be Nuclease-free (e.g. autoclaved 25 minutes twice at +120°C or once 60 minutes at +121°C)

- Thermal cycler with consumables for real-time PCR: 0.2 ml PCR tubes or closed 96-wells PCR plates with optical quality.
- Class II Microbiological Safety Cabinet
- Centrifuge for microtubes, 96-wells plate
- Universal laboratory grinder Mixer Mill or Fast Prep
- Etuve, heating baths or block heaters
- Instrument for homogenous mixing of tubes
- 96 wells plates' agitator
- 1 10 µl pipette, 20 200 µl pipette and 200 1000 µl pipette
- Multichannels pipette 1000 µl
- Nuclease-free filter tips

- Nuclease-free microtubes: 1.5 ml and 2 ml
- 96-well plates (ELISA-like)
- Powder-free Latex gloves
- Metal beads 3 mm
- 96-100% ethanol solution
- Nuclease-free water
- Sterile saline water (NaCl 8.5 g/l)
- ß-mercaptoethanol 14.5 M
- MEM medium + antibiotic (penicillin 100 IU/ml and streptomycin 100 µg/ml)

- RNA extraction kit (individual columns)

- RNeasy[®] Mini Kit (Qiagen, 50 extractions: ref. 74104 or 250 extractions: ref. 74106) or
- QlAamp $^{\otimes}$ Viral RNA (Qiagen, 50 extractions: ref. 52904 or 250 extractions: ref. 52906) or
- NucleoSpin® RNA (Macherey-Nagel, 50 extractions: ref. 740955.50 or 250 extractions: ref. 740955.250)

or

- NucleoSpin® RNA Virus (Macherey-Nagel, 50 extractions: ref. 740956.50 or 250 extractions: ref. 740956.250)

or

- RNA extraction kit (plate columns)

- Nucleospin® 96 Virus (Macherey-Nagel, 2x96 extractions: ref. 740691.2 or 4x96 extractions: ref. 740691.4)
- MN Square-well Block (Macherey-Nagel, 4 plates: ref. 740476), optionnal

or

- RNA extraction kit (8-wells extraction strips)

- Nucleospin® 8 RNA (Macherey-Nagel, 12x8 extractions: ref. 740698 or 60x8 extractions: ref. 740698.5)

or

- Automated DNA/RNA extraction kit using magnetic beads

- ADIAMAG (Bio-X Diagnostics, 200 tests: ref. NADI003)

IV. Recommendation before the analysis of samples

Before starting the test, read the entire protocol and scrupulously respect it.

1. Precautions

Adiagene has elaborated this PCR test with the use of extraction kits from Bio-X Diagnostics, Qiagen, Macherey-Nagel. Other extraction kits can be used with a previous validation.

Follow the supplier's instructions for the storage, the preparation and the use of the extraction reagents.

Some kits include and/or need the use of toxic reagents. These reagents should be use with gloves and into chemical cabinet.

We strongly recommend that only appropriately trained personnel perform this test. Ensure the accuracy and precision of the micropipettes used. The quality of the obtained results depends upon rigorous respect of good laboratory practices.

The PCR generates large amount of amplified DNA. A few molecules of amplified products are sufficient to generate a positive result. It is important to reserve 2 rooms, one for manipulation of samples to be tested, and another one for amplified products analysis. Do not open the PCR tubes after amplification.

Samples for analysis should be handled and disposed of as biological waste. **Take all measures** of security and confinement required for the manipulation of the concerned biological agents.

We recommend using fractions of demineralised and saline water and to autoclave them twice 25 minutes at +120°C or once 60 minutes at +121°C. Take a new fraction for each new manipulation to avoid contamination.

2. Storage of samples and DNA extracts

Samples can be stored a couple of days at +2/8°C. After 2 days, we recommend to store them at <-15°C.

Extracted RNAs are quite sensitive molecules. Extraction is made at room temperature and should be performed as fast as possible to avoid degradations. We then recommend to read the entire protocol before starting the test and to rigorously respect it. Crude extracts should be stored at the end of extraction on melting ice or at $+2/8^{\circ}$ C for few hours, then at $<-15^{\circ}$ C.

3. Samples preparation

A. Nasal swab

Add **2 ml** of MEM medium + antibiotic (in order to allow an ulterior viral culture) or of sterile saline water in the tube of the swab.

Homogenize the swab.

Transfer the liquid in a 2 ml-microtube.

Press the swab to collect as much liquid as possible.

Take 200 µl of sample.

NB1: Store the rest of the liquid at -70°C +/- 10°C for a new analysis or for a viral culture.

NB2: Pools of 3 swabs can be performed but are not recommended for the diagnostic in case of clinical signs.

See § IV for the extraction and purification of RNA following the protocol specific to liquid biological samples.

B. Viral strain culture, supernatant of cellular culture, allantoidal liquids or bronchial liquids

Briefly centrifuge if necessary to clear bronchial liquids.

Take 200 µl of sample.

NB: Store the rest of the liquid at -70°C +/- 10°C for a new analysis or for a viral culture. See § IV for the extraction and purification of RNA following the protocol specific to liquid biological samples.

C. Tissue

RNA from tissue can be extracted according the dedicated protocol presented in following tables.

In case of plugging or inhibitions, RNA can also be extracted according to the protocol for liquid biological samples after the following treatment:

Put **0.1 g** of organ in a 2 ml-microtube with **1 ml** of MEM medium + antibiotic (in order to allow an ulterior viral culture) or of sterile saline water

Add 1 tungsten carbide or stainless-steel bead.

Grind twice at 30 hertz for 3 minutes.

Take 200 µl of sample.

NB: Store the rest of the liquid at -70°C +/- 10°C for a new analysis or for a viral culture. See § IV for the extraction and purification of RNA following the protocol specific to liquid biological samples.

4. Controls to include

The use of controls allows verifying the reliability of the results.

The controls are included per trial of analysis. A trial is defined as all the samples treated in the same conditions.

All the steps of the analysis procedure (extraction+amplification), for all the types of samples, are validated with the association of the controls included in the kit.

- The internal endogenous control (GAPDH) naturally found in the samples allows verifying the extraction and amplification steps of each sample.
- The SIV positive control allows validating the amplification of the target.

Other controls must or could be added:

- Negative control of extraction (required)

To verify the absence of cross-contamination, at least one negative control must be included per trial (e.g. the normative requirement and recommendation for the development and the validation of veterinary PCR NF U47-600 suggests the use of 1 negative control for 24 samples or 4 negative samples for a 96 wells-plate). This control could be a negative matrix, or a buffer used for dilutions.

Positive control of extraction (recommended)

A positive control could be added in each trial. The control is a sample including SIV. It could come from a positive sample available in the laboratory or from a negative sample spiked with a solution of SIV. This positive control will be closed to the limit of detection of the method. It will inform about the fidelity of the obtained results between different trials.

V. Extraction and purification

1. Using RNeasy® kit

	Liquid biological samples	Organs (lungs)			
		Place 20-30 mg of the sample in a microtube.			
Lucia	Add 350 μl of buffer RLT + β-mercaptoethanol (10μl/ml, optional) to the 200 μl of samples prepared as previously described.	Add 350 μl of buffer RLT + β-mercapethanol (10μl/ml) and a metal bead . Grind 2 minutes at 30 Hz			
Lysis	Homogenize by pipetting (~10 times) or by	Briefly centrifuge the lysate.			
	using a mixer such as vortex (~15 seconds).	<i>If necessary, transfert the whole supernantant onto a QIAshredder spin column and centrifuge 2 minutes at 14 000 g.</i>			
Binding	Add 350 µl of ethanol 70% .				
preparation	Homogenizeby pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).				
Transfer to columns and	Identify columns, apply 700 µI of the obtained solution to the corresponding column.	Identify columns, apply the whole obtained solution to the corresponding column.			
binding to the membrane	Centrifuge 1 minute at 8 000 g.	Centrifuge 1 minute at 8 000 g.			
1 st wash	Change the collection tube and add 700 μl of buffer RW1 .				
I" Wasii	Centrifuge 1 minute at 8 000 g.				
2 nd wash	Change the collection tube and add 500 µl of buffer RPE.				
2 Wd311	Centrifuge 1 minutes at 8 000 g.				
3 rd wash	Change the collection tube and add 500 μl of buffer RPE .				
5 Wasii	Centrifuge 3 minutes at 14 000 g.				
Elution	Transfer the column to a microtube. Add 50 µl of Nuclease-free water.				
Liution	Incubate ~2 minutes at room temperature and centrifuge 1 minute at 8 000 g.				
Storage	Close the tubes, identify and store on	ice if using immediately or at <-15°C.			

2. Using QIAamp® Viral RNA kit

	Liquid biological samples	Organs (lungs)		
Lysis	·	Add 560 µl of buffer AVL + RNA carrier and metal bead.		
Binding preparation	Add 560 µl of ethanol 100% . Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).			
Transfer to columns and binding to the membrane	Centrifuge 1 minute at 10 000 g. Change the collection tube, put the rest of the mix on the column and centrifuge 1 minute.			
1 st wash	Change the collection tube and add 500 µl of buffer AW1. Centrifuge 1 minute at 10 000 g.			
2 nd wash	Change the collection tube and add 500 µl of buffer AW2. Centrifuge 1 minutes at 10 000 g.			
Column dry step	Change the collection tube. Centrifuge 3 minutes at 10 000 g.			
Elution	Transfer the column to a microtube. Add 60 µl of buffer AVE . Incubate ~2 minutes at room temperature and centrifuge 1 minute at 10 000 g.			
Storage	Close the tubes, identify and store on ice if using immediately or at <-15°C.			

3. Using Nucleospin® RNA kit

	Liquid biological samples	Organs (lungs)			
		Place 20-30 mg of the sample in a microtube.			
	Add 350 μl of RA1 buffer + β- mercaptoethanol (10μl/ml, optional) to the	Add 350 μl of RA1 buffer + β-mercapethanol (10μl/ml) and a metal bead .			
Lysis	200 μl of samples prepared as previously described.	Grind 2 minutes at 30 Hz			
		Briefly centrifuge the lysate.			
	Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).	<i>If necessary, transfert the whole supernantant</i> onto a filtration column and centrifuge 1 minute at 11 000 g.			
Binding	Add 350 µl of	ethanol 70%.			
preparation	Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).				
Transfer to columns and binding to the	Identify columns, apply 700 µI of the obtained solution to the corresponding column.	Identify columns, apply the whole obtained solution to the corresponding column.			
membrane	Centrifuge 30 seconds at 11 000 g.	Centrifuge 30 seconds at 11 000 g.			
1 st wash	Change the collection tube and add 350 µl of buffer MDB.				
I st wasn	Centrifuge 1 minute at 11 000 g.				
2 nd wash	Add 200 μl of buffer RAW2 .				
Z nd wasn	Centrifuge 30 seconds at 11 000 g.				
3 rd wash	Change the collection tube and add 600 µl of buffer RA3.				
5 " Wasii	Centrifuge 30 seconds at 11 000 g.				
4 th wash	Change the collection tube and add 250 µl of buffer RA3.				
- wasii	Centrifuge 2minutes at 11 000 g.				
Elution	Transfer the column to a microtube. Add 60 μl of Nuclease-free water .				
Elution	Incubate ~2 minutes at room temperatu	ure and centrifuge 1 minute at 11 000 g.			
Storage Close the tubes, identify and store on ice if using immediately or at <-15					

4. Using Nucleospin® RNA Virus kit

	Liquid biological samples	Organs (lungs)		
Lysis	Add 560 µl of buffer RAV1 + carrier prewarmed at +56°C to the 200 µl of samples prepared as previously described. Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).	Place 20-30 mg of the sample in a microtube. Add 560 µl of buffer RAV1 + carrier prewarmed at +56°C and a metal bead. Grind 2 minutes at 30 Hz		
	Incubate at room temperature during 10 minutes. Briefly centrifuge the lysate.			
Binding	Add 560 µl of	ethanol 100%.		
preparation	Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).			
Transfer to	Identify columns, apply $630~\mu l$ of the obtained solution to the corresponding column.			
columns and	Centrifuge 1 minute at 8 000 g.			
binding to the membrane	Change the collection tube, put the rest of the mix on the column and centrifuge 1 minute at 8 000 g.			
1 st	Change the collection tube and add 500 μl of buffer RAW .			
1 st wash	Centrifuge 1 minute at 8 000 g.			
and I	Change the collection tube and add 600 μl of buffer RAV3 .			
2 nd wash	Centrifuge 1 minutes at 8 000 g.			
Column dry	Change the collection tube.			
step	Centrifuge 5 minutes at 11 000 g.			
Florting	Transfer the column to a microtube. Add 50 µl of Nuclease-free water .			
Elution	Incubate ~2 minutes at room temperature and centrifuge 1 minute at 11 000 g.			
Storage	Close the tubes, identify and store on ice if using immediately or at <-15°C.			

5. Using Nucleospin® 8 RNA kit

	Liquid biological samples	Organs (lungs)			
	Place 20-30 mg of the sample in a n				
	Add 350 μl of buffer RA1 + β- mercaptoethanol (10μl/ml, <u>optional</u>) to the	Add 350 μl of buffer RA1 + β-mercapethanol (10μl/ml) and a metal bead .			
Lysis	200 μl of samples prepared as previously described.	Grind 2 minutes at 30 Hz			
		Briefly centrifuge the lysate.			
	Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).	If necessary, transfert the whole supernantant onto a filtration strip and centrifuge 1 minute at 6 000 g.			
Binding	Add 300 μl of buffer RA4 previou :	sly completed with ethanol 100%.			
preparation	Homogenize by pipetting (~10 times) or by using a mixer such as vortex (~15 seconds).				
Transfer to columns and binding to the	Identify columns, apply 700 μl of the obtained solution to the corresponding well of the blue strip.	Identify columns, apply the whole obtained solution of the obtained solution to the corresponding well of the blue strip.			
membrane	Centrifuge 2 minutes at 6 000 g.	Centrifuge 2 minutes at 6 000 g.			
	Transfer strips on non-used trash wells or change the collection plate.				
1 st wash	Add 500 μl of buffer RA3 .				
	Centrifuge 2 minutes at 6 000 g.				
	Transfer strips on non-used trash wells or change the collection plate.				
2 nd wash	Add 500 μl of buffer RA2 .				
	Centrifuge 2 minutes at 6 000 g.				
	Transfer strips on non-used trash wells or change the collection plate.				
3 rd wash	Add 800 μl of buffer RA3 .				
	Centrifuge 2 minutes at 6 000 g.				
	·	vells or change the collection plate.			
4 th wash	Add 500 µl of buffer RA4 .				
	Centrifuge 10 minutes at 6 000 g.				
Elution	Transfer the strips on elution tube strips. Add 75 μl of Nuclease-free water .				
	Incubate ~2 minutes at room temperation	ure and centrifuge 3 minutes at 6 000 g.			
Storage	Close the tubes, identify and store on	ice if using immediately or at <-15°C.			

6. Using Nucleospin® 96 Virus

Three MN Square well block plates are included in each kit. They are used as mix plates or recovery plates. Once they have been used, they can be emptied, decontaminated with HCl 0.4 M during 1 minute, washed with distilled water and autoclaved.

All centrifugations are achieved at 5900 tr/min (5600 to 5800 g) and at room temperature.

Before the beginning of extraction, pre-warm:

- the RAV1 buffer + RNA carrier at +56°C.
- the Nuclease-free water at +70°C.

	Liquid biological samples
	Place 200 µl of sample prepared as previously described in each well of a Round-well Block plate.
Lysis	Add 560 µl of buffer RAV1 + RNA carrier pre-warmed at +56°C + 20 µl of proteinase K . Homogenize the mix 5-times with a multichannel pipette P1000. Close the plate with an adhesive seal Self-adhering PE Foil. Incubate 10 minutes at +70°C.
Binding preparation	Place 560 µl of ethanol 100 % in an MN Square well Block plate. Carefully remove the adhesive seal of the Round-well Block plate containing the samples and transfer the whole content of in the MN Square well Block plate containing ethanol. Homogenize the mix 10-times (very important) with a multichannel pipette P1000.
Transfer to columns and binding to the membrane Place a Nucleospin® Virus Binding plate (blue) on a new MN Square well Block processor of Transfert the whole mix with a multiplication place a new adhesive seal Self adhering PE Foil on the plate. Centrifuge 2 minutes. If the whole mix has not filtered, centrifuge one more time 3 minutes.	
1 st wash	Place the Nucleospin [®] Virus Binding plate on a new MN Square well Block plate. Remove the adhesive seal from the Nucleospin [®] Virus Binding plate. Add 500 µl of buffer RAW in each well. Place a new adhesive seal Self adhering PE foil on the plate. Centrifuge 2 minutes.
2 nd wash	Remove the adhesive seal of the Nucleospin® Virus Binding Plate. Add 900 µl of buffer RAV3 in each well. Place a new adhesive seal Self adhering PE Foil on the plate. Centrifuge 5 minutes.
Column dry step	Place the Nucleospin [®] Virus Binding Plate on an empty and dry 96 well plate (ELISA-like). Centrifuge 10 minutes.
Elution	Place the Nucleospin® Virus Binding Plate on the Rack plate with MN tube strips. Remove the adhesive seal from the plate. Add 100 µl of Nuclease-free water pre-warmed at +70°C in each well of the Nucleospin® Virus Binding plate. Do not use the buffer RE. Incubate ~2 minutes at room temperature and centrifuge 2 minutes.
Storage	Remove the Nucleospin [®] Virus Binding plate. Close the Rack plate with MN tube strips with Caps for strips. Store it on melting ice if analysis is immediately achieved, then at <-15°C.

7. Using ADIAMAG kit

See the NEKF user manual available of the web site mentioned on the certificate of analysis included in the used ADIAVET $^{\text{\tiny{TM}}}$ kit.

VI. Amplification

- a Determine the number samples analysed including the controls (e.g. positive and negative extraction controls, control of amplification (positive and negative controls) and PCR reagent control (NTC)).
- b Defrost the A5 solution at room temperature. Homogenize. Dispense $20 \mu l$ of A5 solution in each PCR tubes or PCR plate wells with a micropipette with a Nuclease-free tip.
- c- Immediately replace the A5 solution tube at <-15°C and in darkness.
- d- For each sample, the extraction negative control (obligatory) and the extraction positive control (recommended) add $5 \mu l$ of purified extract to the 20 μl of A5 solution.

For the controls, add $\mathbf{5} \, \mu \mathbf{I}$, per well, of each solution obtained in § II-3 to the 20 μ I of A5solution. For the PCR reagent control (NTC), nothing is added to the A5 solution.

Immediately replace purified RNA extracts on melting ice or at <-15°C. Take care to have no bubbles in the bottom of the wells.

e- Store the plate or the tubes on melting ice or at +2/8°C until the cycler is programmed and start quickly the run after you have placed the plate or the tubes in the cycler.

The A/H1N1 target is read in FAM. The Internal Control is read in VIC or HEX. The Quencher is non fluorescent. The solution contains a passive reference ROX for the ABI machines. Fluorescence is read during the elongation step (1 minute at 60°C).

The following program is defined for **ABI Prism** thermalcyclers (like 7500, StepOne...) from **Applied Biosystems** (check the "emulation 9600" option if available), for the **Rotorgene** from **Qiagen** and for the **Chromo 4** from **Biorad**:

10 minutes 45°C

10 minutes 95°C

15 seconds at 95°C and 1 minute at 60°C during 45 cycles

This program is concerning the MX3000P and MX3005P of Stratagene:

10 minutes 45°C

10 minutes 95°C

30 seconds at 95°C and 1 minute at 60°C during 45 cycles

Roche diagnostic: LightCycler 2*, LightCycler 480*

* NOTE: The use of LightCycler thermalcyclers requires a calibration manipulation. Adiagene will furnish process chart and reagents required for this calibration.

Contact us if you wish to use other thermalcyclers.

VII. Interpretation of results

1. Definitions


The **« base line »** corresponds to the background of fluorescence and qualifies the non characteristic part of the curve observed during the first cycles.


The « Characteristic amplification curve » qualifies a fluorescence curve with an exponential phase, a linear phase and a plateau phase.

The **« threshold line »** has to be placed over the background in the exponential phase of a characteristic amplification curve or a group of characteristic amplification curves.


The **« threshold cycle » (Ct)** of a well corresponds, for each detected fluorophore, at the crossing point of the threshold line with the fluorescent curve. The Ct value expressed by the machine for each well depends on the threshold position and on the quantity of target sequences initially present in the PCR well.

Example of characteristic amplification curve





Logarithmic scale of Y axis



2. Validation and interpretation of results

Display the FAM curves from the plate and set the threshold value as indicated above. Proceed in the same mean for the VIC or HEX curves.

A. Validation of the run

Amplification is considered to be valid if the following results are obtained for the controls:

Controls	Reagent control (NTC)	A/H1N1 CTL+	SIV CTL-	Extraction negative control	Extraction positive control *
FAM amplification	no	Yes	no	no	yes
VIC/HEX amplification	no	no/yes	yes	no	no/yes
Validation of	Absence of contamination for amplification	Amplification of the A/H1N1 target	Amplification of the IPC target	Absence of contamination for extraction	Extraction and amplification steps

^{*} Optional

The indicative Ct values (FAM and VIC/HEX dyes) of the A/H1N1 CTL+ were indicated in the certificate of analysis of the kit.

B. Result interpretation

RNA extraction and amplification for each sample are considered to be **valid** if at least a characteristic amplification curve is observed for A/H1N1 (FAM) or for the internal control (VIC or HEX).

Example	Α	В	С	D
FAM amplification	no	yes	yes	no
VIC/HEX amplification	yes	no	yes	no
Result	negative	positive	positive	undetermined

The sample is considered as **negative** if a characteristic amplification curve is observed in VIC or HEX without any amplification in FAM (A example).

The sample is considered as **positive** if a characteristic amplification curve is observed in FAM (B example). Internal control can be co-amplified (C example).

A total absence of characteristic amplification curve for a sample (example D) shows a defective RNA extraction (lost or destruction of RNA) or a deficient real-time PCR (inhibitors in the sample, program error or no template added). In this case, we recommend first to repeat the test with pure and tenfold diluted RNA in Nuclease-free water. Then, if the test is still not valid, a new extraction is recommended.

Symbol	Meaning		
REF	Catalogue number		
***	Manufacturer		
1	Upper temperature limit		
><	Use by date		
LOT	Batch code		
[]i	Consult Instructions for Use		
Σ	Contains sufficient for <n> tests</n>		
淡	Keep away from sunlight		
VET	For veterinary in vitro use only – For animal use only		

Bio-X Diagnostics, the logos, ADIAGENE and ADIAVET™ are used, pending and/or registered trademarks belonging to ADIAGENE and/or Bio-X Diagnostics, or one of its subsidiaries, or one of its companies. Any other name or trademark is the property of its respective owner.

